Some patients are using lower-than-recommended dosages of generic weight-loss drugs to slim down while saving money. Despite the disapproval of pharmaceutical companies, doctors and plastic surgeons ...
The FDA recently approved the supplemental biologics license application for teclistamab (Tecvayli; Johnson & Johnson) to treat relapsed/refractory multiple myeloma on a biweekly dosing schedule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback